Abstract Lung cancer, the leading cause of tumor-related mortality worldwide, poses a severe threat to public hygiene. Advances in precise personalized treatment strategies, such as targeted therapy and immunotherapy, present promising prospects for lung cancer cure. Nonetheless, owing to the undefined underlying mechanism of carcinogenesis and unpredictable treatment efficacy, the overall management of lung cancer remains a great concern. N 6 -methyladenosine (m 6 A), identified as pervasive and conserved eukaryotic transcriptional epigenetic modification, has been revealed to exert a noneligible influence on many biological processes through regulation of ribonucleic acid (RNA) splicing, degradation, and translation. Furthermore, intensive investigations suggest that the m 6 A modifications and subsequent alterations to transcripts may be involved in the occurrence and progression of various tumors. In this review, we provide the newest insight into the role of m 6 A modification in lung cancer, focusing on its impact on progression, treatment regulation, and prognosis prediction, which may guide future research based on m 6 A to discover more novel therapeutic targets to combat this fatal disease.
Liang et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: